BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 29378650)

  • 1. Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease.
    Patra K; Soosaipillai A; Sando SB; Lauridsen C; Berge G; Møller I; Grøntvedt GR; Bråthen G; Begcevic I; Moussaud S; Minthon L; Hansson O; Diamandis EP; White LR; Nielsen HM
    Alzheimers Res Ther; 2018 Jan; 10(1):9. PubMed ID: 29378650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease.
    Teuber-Hanselmann S; Rekowski J; Vogelgsang J; von Arnim C; Reetz K; Stang A; Jöckel KH; Wiltfang J; Esselmann H; Otto M; Tumani H; Herring A; Keyvani K
    J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):40-48. PubMed ID: 31371645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased cerebrospinal fluid levels of neurosin (KLK6), an aging-related protease, as a possible new risk factor for Alzheimer's disease.
    Mitsui S; Okui A; Uemura H; Mizuno T; Yamada T; Yamamura Y; Yamaguchi N
    Ann N Y Acad Sci; 2002 Nov; 977():216-23. PubMed ID: 12480753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
    Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
    BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease.
    Johansson P; Almqvist EG; Bjerke M; Wallin A; Johansson JO; Andreasson U; Blennow K; Zetterberg H; Svensson J
    J Alzheimers Dis; 2017; 59(3):1017-1026. PubMed ID: 28697566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.
    Slot RE; Van Harten AC; Kester MI; Jongbloed W; Bouwman FH; Teunissen CE; Scheltens P; Veerhuis R; van der Flier WM
    J Alzheimers Dis; 2017; 56(2):687-697. PubMed ID: 28035918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Adipokines and Biomarkers of Alzheimer's Disease: A Cross-Sectional Study.
    Letra L; Matafome P; Rodrigues T; Duro D; Lemos R; Baldeiras I; Patrício M; Castelo-Branco M; Caetano G; Seiça R; Santana I
    J Alzheimers Dis; 2019; 67(2):725-735. PubMed ID: 30689587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
    Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
    BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
    Diamandis EP; Scorilas A; Kishi T; Blennow K; Luo LY; Soosaipillai A; Rademaker AW; Sjogren M
    Clin Biochem; 2004 Mar; 37(3):230-7. PubMed ID: 14972646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The level of 24-Hydroxycholesteryl Esters is an Early Marker of Alzheimer's Disease.
    Benussi L; Ghidoni R; Dal Piaz F; Binetti G; Di Iorio G; Abrescia P
    J Alzheimers Dis; 2017; 56(2):825-833. PubMed ID: 27983556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia.
    Dukic L; Simundic AM; Martinic-Popovic I; Kackov S; Diamandis A; Begcevic I; Diamandis EP
    Clin Biochem; 2016 Feb; 49(3):213-8. PubMed ID: 26515085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy.
    Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Boström F; Hansson O; Nielsen HM
    PLoS One; 2013; 8(1):e53250. PubMed ID: 23308173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of APOE Genotype on Alzheimer's Disease CSF Biomarkers in a Spanish Population.
    Monge-Argilés JA; Gasparini-Berenguer R; Gutierrez-Agulló M; Muñoz-Ruiz C; Sánchez-Payá J; Leiva-Santana C
    Biomed Res Int; 2016; 2016():1390620. PubMed ID: 27092308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease.
    Zimetti F; Caffarra P; Ronda N; Favari E; Adorni MP; Zanotti I; Bernini F; Barocco F; Spallazzi M; Galimberti D; Ricci C; Ruscica M; Corsini A; Ferri N
    J Alzheimers Dis; 2017; 55(1):315-320. PubMed ID: 27662294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.